These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36901099)

  • 1. Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection.
    Yu CL; Carvalho AF; Thompson T; Tsai TC; Tseng PT; Hsu CW; Tu YK; Yang SN; Hsu TW; Yeh TC; Liang CS
    Int J Environ Res Public Health; 2023 Feb; 20(5):. PubMed ID: 36901099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.
    Lenze EJ; Mattar C; Zorumski CF; Stevens A; Schweiger J; Nicol GE; Miller JP; Yang L; Yingling M; Avidan MS; Reiersen AM
    JAMA; 2020 Dec; 324(22):2292-2300. PubMed ID: 33180097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of fluvoxamine in patients with COVID-19: A systematic review and meta-analysis from randomized controlled trials.
    Zhou Q; Zhao G; Pan Y; Zhang Y; Ni Y
    PLoS One; 2024; 19(5):e0300512. PubMed ID: 38753761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
    Reis G; Dos Santos Moreira-Silva EA; Silva DCM; Thabane L; Milagres AC; Ferreira TS; Dos Santos CVQ; de Souza Campos VH; Nogueira AMR; de Almeida APFG; Callegari ED; de Figueiredo Neto AD; Savassi LCM; Simplicio MIC; Ribeiro LB; Oliveira R; Harari O; Forrest JI; Ruton H; Sprague S; McKay P; Glushchenko AV; Rayner CR; Lenze EJ; Reiersen AM; Guyatt GH; Mills EJ;
    Lancet Glob Health; 2022 Jan; 10(1):e42-e51. PubMed ID: 34717820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvoxamine in Nonhospitalized Patients With Acute COVID-19 Infection and the Lack of Efficacy in Reducing Rates of Hospitalization, Mechanical Ventilation, and Mortality in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis.
    Bhuta S; Khokher W; Kesireddy N; Iftikhar S; Beran A; Mhanna M; Patel NJ; Patel M; Burmeister C; Assaly R
    Am J Ther; 2022 May-Jun 01; 29(3):e298-e304. PubMed ID: 35383578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.
    Prasanth MI; Wannigama DL; Reiersen AM; Thitilertdecha P; Prasansuklab A; Tencomnao T; Brimson S; Brimson JM
    Sci Rep; 2024 Jun; 14(1):13462. PubMed ID: 38862591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvoxamine for the Early Treatment of COVID-19: A Meta-analysis of Randomized Clinical Trials.
    Guo CM; Harari O; Chernecki C; Thorlund K; Forrest JI
    Am J Trop Med Hyg; 2022 Mar; 106(5):1315-20. PubMed ID: 35263710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials.
    Vatvani AD; Kurniawan A; Hariyanto TI
    Ann Pharmacother; 2023 Dec; 57(12):1389-1397. PubMed ID: 37002592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial.
    Reiersen AM; Mattar C; Bender Ignacio RA; Boulware DR; Lee TC; Hess R; Lankowski AJ; McDonald EG; Miller JP; Powderly WG; Pullen MF; Rado JT; Rich MW; Schiffer JT; Schweiger J; Spivak AM; Stevens A; Vigod SN; Agarwal P; Yang L; Yingling M; Gettinger TR; Zorumski CF; Lenze EJ
    Open Forum Infect Dis; 2023 Aug; 10(8):ofad419. PubMed ID: 37622035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
    Facente SN; Reiersen AM; Lenze EJ; Boulware DR; Klausner JD
    Drugs; 2021 Dec; 81(18):2081-2089. PubMed ID: 34851510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis.
    Lu LC; Chao CM; Chang SP; Lan SH; Lai CC
    J Infect Public Health; 2022 Nov; 15(11):1259-1264. PubMed ID: 36272390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial.
    Seo H; Kim H; Bae S; Park S; Chung H; Sung HS; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Son KY; Chong YP
    Infect Chemother; 2022 Mar; 54(1):102-113. PubMed ID: 35384422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressants for COVID-19: A systematic review.
    Zheng W; Sun HL; Cai H; Zhang Q; Ng CH; Xiang YT
    J Affect Disord; 2022 Jun; 307():108-114. PubMed ID: 35339571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.
    Wen W; Chen C; Tang J; Wang C; Zhou M; Cheng Y; Zhou X; Wu Q; Zhang X; Feng Z; Wang M; Mao Q
    Ann Med; 2022 Dec; 54(1):516-523. PubMed ID: 35118917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis.
    Lee TC; Vigod S; Bortolussi-Courval É; Hanula R; Boulware DR; Lenze EJ; Reiersen AM; McDonald EG
    JAMA Netw Open; 2022 Apr; 5(4):e226269. PubMed ID: 35385087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating fluvoxamine for the outpatient treatment of COVID-19: A systematic review and meta-analysis.
    Deng J; Moskalyk M; Zuo QK; Garcia C; Abbas U; Ramaraju HB; Rayner D; Park YJ; Heybati K; Zhou F; Lohit S
    Rev Med Virol; 2024 Jan; 34(1):e2501. PubMed ID: 38148036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary artery perfusion versus no perfusion during cardiopulmonary bypass for open heart surgery in adults.
    Buggeskov KB; Grønlykke L; Risom EC; Wei ML; Wetterslev J
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011098. PubMed ID: 29419895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial).
    Siripongboonsitti T; Tawinprai K; Payoong P; Mahanonda N
    J Infect Public Health; 2023 Dec; 16(12):2010-2016. PubMed ID: 37890224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.